Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome

Aquaporin-4 immunoglobulin G (AQP4-IgG) antibody-positive neuromyelitis optica spectrum disorders (NMOSD) are frequently associated with other autoimmune disorders, including systemic lupus erythematosus (SLE). Eculizumab (ECU) is a highly effective long-term treatment for NMOSD. However, ECU is kno...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Doubrovinskaia, Sofia (VerfasserIn) , Korporal-Kuhnke, Mirjam (VerfasserIn) , Jarius, Sven (VerfasserIn) , Haas, Jürgen (VerfasserIn) , Wildemann, Brigitte (VerfasserIn)
Dokumenttyp: Article (Journal) Editorial
Sprache:Englisch
Veröffentlicht: 14 November 2023
In: Journal of neurology
Year: 2024, Jahrgang: 271, Heft: 5, Pages: 2866-2870
ISSN:1432-1459
DOI:10.1007/s00415-023-12071-9
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00415-023-12071-9
Volltext
Verfasserangaben:S. Doubrovinskaja, M. Korporal-Kuhnke, S. Jarius, J. Haas, B. Wildemann

MARC

LEADER 00000caa a22000002c 4500
001 1878583867
003 DE-627
005 20240710141124.0
007 cr uuu---uuuuu
008 240122s2023 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00415-023-12071-9  |2 doi 
035 |a (DE-627)1878583867 
035 |a (DE-599)KXP1878583867 
035 |a (OCoLC)1425207551 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Doubrovinskaia, Sofia  |d 1993-  |e VerfasserIn  |0 (DE-588)1248728602  |0 (DE-627)1784562092  |4 aut 
245 1 0 |a Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD)  |b fatal outcome  |c S. Doubrovinskaja, M. Korporal-Kuhnke, S. Jarius, J. Haas, B. Wildemann 
264 1 |c 14 November 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 22.01.2024 
520 |a Aquaporin-4 immunoglobulin G (AQP4-IgG) antibody-positive neuromyelitis optica spectrum disorders (NMOSD) are frequently associated with other autoimmune disorders, including systemic lupus erythematosus (SLE). Eculizumab (ECU) is a highly effective long-term treatment for NMOSD. However, ECU is known to increase significantly the risk of infection with encapsulated bacteria and sepsis. Recently, increased insulin resistance (IR) in patients with NMOSD has been suggested. Type B IR (TBIR) is a rare autoimmune condition often accompanying or preceding SLE. TBIR has not yet been reported in NMOSD. Objective: To report an ECU-treated patient with AQP4-IgG-positive NMOSD who developed fatal septic complications after the emergence of TBIR. Methods: Description of the clinical course over a period of 8 years. Results: A female patient was diagnosed with NMOSD at the age of 16 years. A variety of disease-modifying drugs failed to achieve sufficient disease control, resulting in severe tetraparesis. Treatment with ECU was started 6 years after NMOSD diagnosis and stabilized the disease. The patient developed TBIR 8 months after initiation of ECU therapy. Following high-dose intravenous methylprednisolone therapy for a clinical relapse and three further courses of ECU, the patient was admitted with severe pneumonia caused by the encapsulated bacterium Klebsiella pneumoniae and hypoglycemia. Despite multimodal therapy, the patient died from sepsis-related multiorgan failure 18 months after initiation of ECU. Conclusions: TBIR should be considered as differential diagnosis in patients with NMOSD presenting with disturbed glucose metabolism, irrespective of the presence of SLE. More real-world data are needed on the risk/benefit ratio of ECU treatment in patients who have co-existing autoimmune comorbidities that may compromise immune function. Strategies to mitigate the risk of serious infection in patients treated with ECU are discussed. 
650 4 |a Aquaporin-4 antibodies (AQP4-IgG) 
650 4 |a Death 
650 4 |a Eculizumab 
650 4 |a Fatal outcome 
650 4 |a Infections 
650 4 |a Neuromyelitis optica spectrum disorders (NMOSD) 
650 4 |a Pneumonia 
650 4 |a Ravulizumab 
650 4 |a Sepsis 
650 4 |a Type B insulin resistance (TBIR) 
700 1 |a Korporal-Kuhnke, Mirjam  |d 1975-  |e VerfasserIn  |0 (DE-588)129891851  |0 (DE-627)483343579  |0 (DE-576)297889583  |4 aut 
700 1 |a Jarius, Sven  |e VerfasserIn  |0 (DE-588)1054615918  |0 (DE-627)791654818  |0 (DE-576)410367478  |4 aut 
700 1 |a Haas, Jürgen  |e VerfasserIn  |0 (DE-588)1073216810  |0 (DE-627)828662290  |0 (DE-576)434731749  |4 aut 
700 1 |a Wildemann, Brigitte  |e VerfasserIn  |0 (DE-588)110203844  |0 (DE-627)510150004  |0 (DE-576)171831330  |4 aut 
773 0 8 |i Enthalten in  |t Journal of neurology  |d [Darmstadt] : Steinkopff, 1974  |g 271(2024), 5, Seite 2866-2870  |h Online-Ressource  |w (DE-627)242065155  |w (DE-600)1421299-7  |w (DE-576)065026500  |x 1432-1459  |7 nnas  |a Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) fatal outcome 
773 1 8 |g volume:271  |g year:2024  |g number:5  |g pages:2866-2870  |a Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) fatal outcome 
856 4 0 |u https://doi.org/10.1007/s00415-023-12071-9  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20240122 
993 |a Editorial 
994 |a 2023 
998 |g 110203844  |a Wildemann, Brigitte  |m 110203844:Wildemann, Brigitte  |d 910000  |d 911100  |d 50000  |e 910000PW110203844  |e 911100PW110203844  |e 50000PW110203844  |k 0/910000/  |k 1/910000/911100/  |k 0/50000/  |p 5  |y j 
998 |g 1073216810  |a Haas, Jürgen  |m 1073216810:Haas, Jürgen  |d 910000  |d 911100  |d 50000  |e 910000PH1073216810  |e 911100PH1073216810  |e 50000PH1073216810  |k 0/910000/  |k 1/910000/911100/  |k 0/50000/  |p 4 
998 |g 1054615918  |a Jarius, Sven  |m 1054615918:Jarius, Sven  |d 910000  |d 911100  |e 910000PJ1054615918  |e 911100PJ1054615918  |k 0/910000/  |k 1/910000/911100/  |p 3 
998 |g 129891851  |a Korporal-Kuhnke, Mirjam  |m 129891851:Korporal-Kuhnke, Mirjam  |d 910000  |d 911100  |e 910000PK129891851  |e 911100PK129891851  |k 0/910000/  |k 1/910000/911100/  |p 2 
998 |g 1248728602  |a Doubrovinskaia, Sofia  |m 1248728602:Doubrovinskaia, Sofia  |d 910000  |d 911100  |e 910000PD1248728602  |e 911100PD1248728602  |k 0/910000/  |k 1/910000/911100/  |p 1  |x j 
999 |a KXP-PPN1878583867  |e 4464752209 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1878583867","relHost":[{"part":{"year":"2024","pages":"2866-2870","issue":"5","volume":"271","text":"271(2024), 5, Seite 2866-2870"},"title":[{"title_sort":"Journal of neurology","title":"Journal of neurology"}],"id":{"eki":["242065155"],"issn":["1432-1459"],"zdb":["1421299-7"]},"note":["Gesehen am 14.03.25","Ungezählte Beil.: Supplement"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng","ger"],"pubHistory":["Volume 207, issue 1 (March 1974)-"],"origin":[{"publisher":"Steinkopff ; Springer ; Steinkopff [u.a.] ; Springer-Medizin-Verl.","dateIssuedKey":"1974","dateIssuedDisp":"1974-","publisherPlace":"[Darmstadt] ; Berlin ; Heidelberg [u.a.] ; Darmstadt ; Heidelberg"}],"disp":"Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) fatal outcomeJournal of neurology","recId":"242065155","physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"role":"aut","given":"Sofia","family":"Doubrovinskaia","display":"Doubrovinskaia, Sofia"},{"display":"Korporal-Kuhnke, Mirjam","given":"Mirjam","role":"aut","family":"Korporal-Kuhnke"},{"display":"Jarius, Sven","role":"aut","given":"Sven","family":"Jarius"},{"family":"Haas","given":"Jürgen","role":"aut","display":"Haas, Jürgen"},{"display":"Wildemann, Brigitte","role":"aut","given":"Brigitte","family":"Wildemann"}],"origin":[{"dateIssuedDisp":"14 November 2023","dateIssuedKey":"2023"}],"name":{"displayForm":["S. Doubrovinskaja, M. Korporal-Kuhnke, S. Jarius, J. Haas, B. Wildemann"]},"title":[{"subtitle":"fatal outcome","title":"Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD)","title_sort":"Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD)"}],"id":{"doi":["10.1007/s00415-023-12071-9"],"eki":["1878583867"]},"note":["Gesehen am 22.01.2024"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} 
SRT |a DOUBROVINSNEWLYEMERG1420